不向美国电信服务分发或在美国传播
Onco-Innovations Limited (CBOE CA: ONCO)(法兰克福: W1H, WKN: A3EKSZ)(OTCQB: ONNVF)（&#34; Onco&#34;或&#34; 公司&#34;）宣布其计划完成一项非承销私募（&#34; 私募&#34;），最多发行 2,272,727 个单位（&#34; 单位&#34;），每个单位的价格为 0.88 美元，总募集金额最高可达 2,000,000 美元。每个单位将由一股普通股（每股称为&#34;股份&#34;）和半个普通股认购权证（每个完整的认购权证称为&#34;认购权证&#34;）组成，每个认购权证使持有人有权以 1.10 美元的行使价格购买一股股份，有效期为三十六（36）个月。
公司还计划向一名与公司没有关联的第三方发行相当于私募中发行股份总数 1.0% 的股份（&#34;管理费股份&#34;），作为其协助私募的行政费用。
在私募过程中，公司可能会支付介绍费和/或按与认购权证相同的条款发行介绍权证，给予那些帮助引入认购者的合格方。
私募的完成需满足某些条件，包括但不限于获得所有必要的监管和其他批准。根据适用的证券法，私募中发行的所有证券将受到四个月零一天的持有期限制。公司计划将私募的收益用于一般企业和营运资金用途，包括追求公司的运营和研发目标以及投资者关系目的。
此处描述的证券尚未并将不会根据美国 1933 年证券法及其修正案或任何美国州证券法进行注册，且在未注册或未获得相关豁免的情况下不得在美国提供或出售。本新闻稿不构成在美国或任何此类提供、招揽或销售将是非法的司法管辖区内出售或招揽购买任何证券的要约。
关于 Onco-Innovations Limited
Onco-Innovations 是一家总部位于加拿大的公司，致力于癌症研究和治疗，专注于肿瘤学。Onco 的使命是通过开创性的研究和创新解决方案追求癌症的预防和治疗。该公司已获得针对实体肿瘤的专利技术的全球独家许可。
代表 Onco-Innovations Limited，
&#34; Thomas O'Shaughnessy&#34;
首席执行官
如需更多信息，请联系：
Thomas O'Shaughnessy
首席执行官
电话：+ 1 888 261 8055
investors@oncoinnovations.com
CSE 未审查此发布内容，也不对其准确性或充分性承担责任。
前瞻性声明警告。本新闻稿包含前瞻性声明，包括与私募相关的一般性声明，以及对资金预期使用和完成日期的预期，以及对公司业务和计划的一般性声明，以及其他非历史事实的声明。前瞻性声明通常通过&#34;将&#34;、&#34;可能&#34;、&#34;潜在&#34;、&#34;应该&#34;、&#34;预期&#34;、&#34;期望&#34;及类似表达来识别。除历史事实声明外，本发布中包含的所有声明均为前瞻性声明，涉及风险和不确定性。无法保证这些声明将被证明是准确的，实际结果和未来事件可能与这些声明中预期的有实质性差异。可能导致实际结果与公司预期有实质性差异的重要因素包括未能按预期完成私募，或根本未能完成，预期收益可能低于预期，未能获得与私募相关的监管批准，以及公司不时向证券监管机构提交的文件中详细列出的其他风险。读者应注意，准备任何前瞻性信息时所使用的假设可能被证明是错误的。事件或情况可能导致实际结果与预测有实质性差异，原因是众多已知和未知的风险、不确定性和其他因素，其中许多超出了公司的控制范围。读者应谨慎对待任何前瞻性信息。尽管管理层在准备时认为这些信息是合理的，但可能被证明是错误的，实际结果可能与预期有实质性差异。本新闻稿中包含的前瞻性声明明确受到此警告声明的限制。本新闻稿中包含的前瞻性声明是截至本新闻稿日期作出的，公司将根据适用法律的明确要求，公开更新或修订任何包含的前瞻性声明。
来源： Onco-Innovations Limited
查看原始新闻稿，请访问 ACCESS Newswire
<img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEzMDM4Mg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEzMDM4Mg"/>

Onco-Innovations Limited 宣布进行一项非承销私人配售，最多发行 2,272,727 个单位，每个单位价格为 0.88 美元，目标总收益为 200 万美元。每个单位包括一股普通股和半个认股权证，认股权证的行使价格为 1.10 美元，有效期为 36 个月。募集的资金将用于一般企业用途和研发。该配售需获得监管机构的批准，证券将有四个月的锁定期。该公司专注于癌症研究，并拥有针对实体肿瘤的专利技术的独占权

Not for distribution to United States wire services or for dissemination in the United States
<div class="lb-trans">不向美国电信服务分发或在美国传播
</div>Onco-Innovations Limited (CBOE CA: ONCO)(Frankfurt: W1H, WKN: A3EKSZ)(OTCQB: ONNVF) (&#34; Onco&#34; or the &#34; Company&#34;) announces that it intends to complete a non-brokered private placement (the &#34; Private Placement&#34;) of up to 2,272,727 units of the Company (the &#34; Units&#34;) at a price of $0.88 per Unit, for aggregate gross proceeds of up to $2,000,000. Each Unit shall consist of one common share (each a &#34;Share&#34;) and one-half of one common share purchase warrant (each whole warrant, a &#34;Warrant&#34;), with each Warrant entitling the holder to purchase one Share at an exercise price of $1.10 for a period of thirty-six (36) months.
<div class="lb-trans">Onco-Innovations Limited (CBOE CA: ONCO)(法兰克福: W1H, WKN: A3EKSZ)(OTCQB: ONNVF)（&#34; Onco&#34;或&#34; 公司&#34;）宣布其计划完成一项非承销私募（&#34; 私募&#34;），最多发行 2,272,727 个单位（&#34; 单位&#34;），每个单位的价格为 0.88 美元，总募集金额最高可达 2,000,000 美元。每个单位将由一股普通股（每股称为&#34;股份&#34;）和半个普通股认购权证（每个完整的认购权证称为&#34;认购权证&#34;）组成，每个认购权证使持有人有权以 1.10 美元的行使价格购买一股股份，有效期为三十六（36）个月。
</div>The Company also intends to issue Shares equal to 1.0% of the total of Shares issued in the Private Placement (the &#34;Admin Fee Shares&#34;) to an arm's-length third party, as an administrative fee for their assistance with the Private Placement.
<div class="lb-trans">公司还计划向一名与公司没有关联的第三方发行相当于私募中发行股份总数 1.0% 的股份（&#34;管理费股份&#34;），作为其协助私募的行政费用。
</div>In connection with the Private Placement, the Company may pay finders' fees and/or issue finders' warrants on the same terms as the Warrants, to eligible parties who have assisted by introducing subscribers to the Private Placement.
<div class="lb-trans">在私募过程中，公司可能会支付介绍费和/或按与认购权证相同的条款发行介绍权证，给予那些帮助引入认购者的合格方。
</div>Closing of the Private Placement is subject to certain conditions, including, but not limited to, the receipt of all necessary regulatory and other approvals. All securities issued pursuant to Private Placement will be subject to a hold period of four months and one day pursuant to applicable securities laws. The Company intends to use the proceeds of the Private Placement for general corporate and working capital purposes, including in pursuit of the Company's operational and research and development objectives and for investor relations purposes.
<div class="lb-trans">私募的完成需满足某些条件，包括但不限于获得所有必要的监管和其他批准。根据适用的证券法，私募中发行的所有证券将受到四个月零一天的持有期限制。公司计划将私募的收益用于一般企业和营运资金用途，包括追求公司的运营和研发目标以及投资者关系目的。
</div>The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any U.S. state securities laws, and may not be offered or sold in the United States absent registration or available exemptions from such registration requirements. This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities in the United States, or in any jurisdiction in which such offer, solicitation or sale would be unlawful.
<div class="lb-trans">此处描述的证券尚未并将不会根据美国 1933 年证券法及其修正案或任何美国州证券法进行注册，且在未注册或未获得相关豁免的情况下不得在美国提供或出售。本新闻稿不构成在美国或任何此类提供、招揽或销售将是非法的司法管辖区内出售或招揽购买任何证券的要约。
</div>About Onco-Innovations Limited
<div class="lb-trans">关于 Onco-Innovations Limited
</div>Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.
<div class="lb-trans">Onco-Innovations 是一家总部位于加拿大的公司，致力于癌症研究和治疗，专注于肿瘤学。Onco 的使命是通过开创性的研究和创新解决方案追求癌症的预防和治疗。该公司已获得针对实体肿瘤的专利技术的全球独家许可。
</div>ON BEHALF OF ONCO-INNOVATIONS LIMITED,
<div class="lb-trans">代表 Onco-Innovations Limited，
</div>&#34; Thomas O'Shaughnessy&#34;
<div class="lb-trans">&#34; Thomas O'Shaughnessy&#34;
</div>Chief Executive Officer
<div class="lb-trans">首席执行官
</div>For more information, please contact:
<div class="lb-trans">如需更多信息，请联系：
</div>Thomas O'Shaughnessy
<div class="lb-trans">Thomas O'Shaughnessy
</div>Chief Executive Officer
<div class="lb-trans">首席执行官
</div>Tel: + 1 888 261 8055
<div class="lb-trans">电话：+ 1 888 261 8055
</div>investors@oncoinnovations.com
<div class="lb-trans">investors@oncoinnovations.com
</div>The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.
<div class="lb-trans">CSE 未审查此发布内容，也不对其准确性或充分性承担责任。
</div>Forward-Looking Statements Caution. This news release contains forward-looking statements, including in relation to the Private Placement generally, and the anticipated use of funds and closing date thereof, as well as to the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as &#34;will&#34;, &#34;may&#34;, &#34;potential&#34;, &#34;should&#34;, &#34;anticipate&#34;, &#34;expects&#34; and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to complete the Private Placement as contemplated, or at all, that the anticipated proceeds may be lower than expected, the failure to receive regulatory approval in respect of the Private Placement, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward- looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
<div class="lb-trans">前瞻性声明警告。本新闻稿包含前瞻性声明，包括与私募相关的一般性声明，以及对资金预期使用和完成日期的预期，以及对公司业务和计划的一般性声明，以及其他非历史事实的声明。前瞻性声明通常通过&#34;将&#34;、&#34;可能&#34;、&#34;潜在&#34;、&#34;应该&#34;、&#34;预期&#34;、&#34;期望&#34;及类似表达来识别。除历史事实声明外，本发布中包含的所有声明均为前瞻性声明，涉及风险和不确定性。无法保证这些声明将被证明是准确的，实际结果和未来事件可能与这些声明中预期的有实质性差异。可能导致实际结果与公司预期有实质性差异的重要因素包括未能按预期完成私募，或根本未能完成，预期收益可能低于预期，未能获得与私募相关的监管批准，以及公司不时向证券监管机构提交的文件中详细列出的其他风险。读者应注意，准备任何前瞻性信息时所使用的假设可能被证明是错误的。事件或情况可能导致实际结果与预测有实质性差异，原因是众多已知和未知的风险、不确定性和其他因素，其中许多超出了公司的控制范围。读者应谨慎对待任何前瞻性信息。尽管管理层在准备时认为这些信息是合理的，但可能被证明是错误的，实际结果可能与预期有实质性差异。本新闻稿中包含的前瞻性声明明确受到此警告声明的限制。本新闻稿中包含的前瞻性声明是截至本新闻稿日期作出的，公司将根据适用法律的明确要求，公开更新或修订任何包含的前瞻性声明。
</div>SOURCE: Onco-Innovations Limited
<div class="lb-trans">来源： Onco-Innovations Limited
</div>View the original press release on ACCESS Newswire
<div class="lb-trans">查看原始新闻稿，请访问 ACCESS Newswire
</div><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEzMDM4Mg" alt="" original-src="https://app.accessnewswire.com/img.ashx?id=1130382"/>

Onco-Innovations 宣布进行私募 | ONNVF 股票新闻